Baidu (BIDU) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Baidu (BIDU)

BIDU 119.30

+0.4%

Dec 16 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Julius Wong	11/22/2021 7:46:23 AM
	1 Recommendation Recommended By Frank Sully of 2098

Sanofi and Baidu ink license agreement for next-gen mRNA therapies and vaccines Nov. 22, 2021 7:26 AM ET Baidu, Inc. (BIDU), SNY By: Dulan Lokuwithana, SA News Editor libre de droit/iStock via Getty Images Baidu (NASDAQ: BIDU) and Sanofi (NASDAQ: SNY) announced an agreement to integrate Baidu's messenger ribonucleic acid (mRNA) design optimization platform, LinearDesign into French pharma giant’s product design pipeline. Developed in 2020, LinearDesign is an algorithm for mRNA sequence design. Under the partnership, Sanofi ( SNY) will use the platform to optimize mRNA sequences in the development of therapeutics and preventative approaches. “We have already seen that combining mRNA with computational biology tools makes the process quicker and more effective and has the potential to further transform drug discovery,” remarked Tian Wu, Baidu Corporate Vice President. The company is honored to team up with Sanofi “to bring life-saving mRNA therapies and vaccines to the global healthcare community," Wu added.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next